ECSP22057324A - Compuesto de piridazinil-tiazolcarboxamida - Google Patents
Compuesto de piridazinil-tiazolcarboxamidaInfo
- Publication number
- ECSP22057324A ECSP22057324A ECSENADI202257324A ECDI202257324A ECSP22057324A EC SP22057324 A ECSP22057324 A EC SP22057324A EC SENADI202257324 A ECSENADI202257324 A EC SENADI202257324A EC DI202257324 A ECDI202257324 A EC DI202257324A EC SP22057324 A ECSP22057324 A EC SP22057324A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- compound
- cancer
- antibodies
- activation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporciona un compuesto ?til como principio activo de una composici?n farmac?utica para el tratamiento del c?ncer relacionado con la activaci?n de c?lulas inmunitarias o el c?ncer que ofrece resistencia a un tratamiento con anticuerpos anti-PD-1/anticuerpos anti-PD-L1. Los inventores de la presente han realizado estudios sobre un compuesto ?til como principio activo de una composici?n farmac?utica para el tratamiento del c?ncer relacionado con la activaci?n de c?lulas inmunitarias o del c?ncer que ofrece resistencia a un tratamiento con anticuerpos anti-PD-1/anticuerpos anti-PD-L1 y descubrieron que un compuesto de piridazinil-tiazolcarboxamida tiene efecto inhibitorio sobre DGKz (DGKzeta), lo que da lugar a la consecuci?n de la presente invenci?n. El compuesto de piridazinil-tiazolcarboxamida de la presente invenci?n tiene efecto inhibitorio sobre DGKz; y puede usarse como agente terap?utico para el tratamiento del c?ncer relacionado con la activaci?n de c?lulas inmunitarias o del c?ncer que ofrece resistencia a un tratamiento con anticuerpos anti-PD-1/anticuerpos anti-PD-L1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019233673 | 2019-12-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22057324A true ECSP22057324A (es) | 2022-08-31 |
Family
ID=76574296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202257324A ECSP22057324A (es) | 2019-12-25 | 2022-07-21 | Compuesto de piridazinil-tiazolcarboxamida |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220315603A1 (es) |
| EP (1) | EP4083038B1 (es) |
| JP (1) | JP6948659B1 (es) |
| KR (1) | KR20220119702A (es) |
| CN (3) | CN115590854B (es) |
| AR (1) | AR120896A1 (es) |
| AU (1) | AU2020413997A1 (es) |
| BR (1) | BR112022012637A2 (es) |
| CA (1) | CA3165889A1 (es) |
| CL (1) | CL2022001752A1 (es) |
| CO (1) | CO2022009124A2 (es) |
| CR (1) | CR20220328A (es) |
| DO (1) | DOP2022000137A (es) |
| EC (1) | ECSP22057324A (es) |
| IL (1) | IL294136A (es) |
| JO (1) | JOP20220163A1 (es) |
| MX (1) | MX2022007993A (es) |
| PE (1) | PE20230163A1 (es) |
| TW (3) | TW202413375A (es) |
| WO (1) | WO2021132422A1 (es) |
| ZA (1) | ZA202207543B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022012625A2 (pt) | 2019-12-24 | 2022-09-06 | Carna Biosciences Inc | Compostos moduladores de diacilglicerol quinase |
| AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| BR112022019057A2 (pt) | 2020-04-24 | 2022-11-08 | Bayer Ag | Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune |
| WO2022114164A1 (ja) | 2020-11-30 | 2022-06-02 | アステラス製薬株式会社 | ヘテロアリールカルボキシアミド化合物 |
| AU2022297373A1 (en) | 2021-06-23 | 2024-01-04 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP2024522698A (ja) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN114621214B (zh) * | 2022-04-25 | 2024-04-26 | 宜春学院 | 一种抗菌席夫碱n-酰化物及其制备方法和应用 |
| US20240217989A1 (en) * | 2022-11-18 | 2024-07-04 | Incyte Corporation | Heteroaryl Fluoroalkenes As DGK Inhibitors |
| WO2024151346A1 (en) * | 2023-01-12 | 2024-07-18 | Incyte Corporation | Heteroaryl fluoroalkenes as dgk inhibitors |
| WO2024165470A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors |
| WO2024199387A1 (zh) * | 2023-03-30 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的化合物 |
| WO2024208198A1 (zh) * | 2023-04-06 | 2024-10-10 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的噻唑类化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381401B2 (en) | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| NZ590359A (en) * | 2005-01-25 | 2012-08-31 | Synta Pharmaceuticals Corp | Pyrazine compounds for inflammation and immune-related uses |
| JP2009524677A (ja) * | 2006-01-25 | 2009-07-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 |
| WO2007123269A1 (ja) | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | アゾールカルボキサミド誘導体 |
| WO2008054702A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
| KR20210024586A (ko) * | 2018-06-27 | 2021-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| WO2022114164A1 (ja) * | 2020-11-30 | 2022-06-02 | アステラス製薬株式会社 | ヘテロアリールカルボキシアミド化合物 |
-
2020
- 2020-12-23 AR ARP200103641A patent/AR120896A1/es unknown
- 2020-12-24 EP EP20906466.6A patent/EP4083038B1/en active Active
- 2020-12-24 CN CN202211308268.2A patent/CN115590854B/zh active Active
- 2020-12-24 JP JP2021531562A patent/JP6948659B1/ja active Active
- 2020-12-24 TW TW112145679A patent/TW202413375A/zh unknown
- 2020-12-24 CN CN202080011114.XA patent/CN113365994B/zh active Active
- 2020-12-24 WO PCT/JP2020/048337 patent/WO2021132422A1/ja active Application Filing
- 2020-12-24 JO JOP/2022/0163A patent/JOP20220163A1/ar unknown
- 2020-12-24 US US17/427,426 patent/US20220315603A1/en active Pending
- 2020-12-24 IL IL294136A patent/IL294136A/en unknown
- 2020-12-24 TW TW109146029A patent/TW202136275A/zh unknown
- 2020-12-24 CN CN202211308277.1A patent/CN115626919A/zh active Pending
- 2020-12-24 MX MX2022007993A patent/MX2022007993A/es unknown
- 2020-12-24 BR BR112022012637A patent/BR112022012637A2/pt unknown
- 2020-12-24 PE PE2022001161A patent/PE20230163A1/es unknown
- 2020-12-24 TW TW112145680A patent/TW202413376A/zh unknown
- 2020-12-24 AU AU2020413997A patent/AU2020413997A1/en active Pending
- 2020-12-24 KR KR1020227025714A patent/KR20220119702A/ko unknown
- 2020-12-24 CA CA3165889A patent/CA3165889A1/en active Pending
- 2020-12-24 CR CR20220328A patent/CR20220328A/es unknown
-
2022
- 2022-06-24 CL CL2022001752A patent/CL2022001752A1/es unknown
- 2022-06-24 DO DO2022000137A patent/DOP2022000137A/es unknown
- 2022-06-30 CO CONC2022/0009124A patent/CO2022009124A2/es unknown
- 2022-07-07 ZA ZA2022/07543A patent/ZA202207543B/en unknown
- 2022-07-21 EC ECSENADI202257324A patent/ECSP22057324A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022012637A2 (pt) | 2022-09-06 |
| CO2022009124A2 (es) | 2022-07-19 |
| CA3165889A1 (en) | 2021-07-01 |
| DOP2022000137A (es) | 2022-11-30 |
| EP4083038A1 (en) | 2022-11-02 |
| TW202136275A (zh) | 2021-10-01 |
| PE20230163A1 (es) | 2023-02-01 |
| JPWO2021132422A1 (ja) | 2021-12-23 |
| KR20220119702A (ko) | 2022-08-30 |
| JOP20220163A1 (ar) | 2023-01-30 |
| CN113365994B (zh) | 2024-08-09 |
| AR120896A1 (es) | 2022-03-30 |
| TW202413375A (zh) | 2024-04-01 |
| CL2022001752A1 (es) | 2023-03-10 |
| CR20220328A (es) | 2022-08-30 |
| EP4083038B1 (en) | 2024-10-30 |
| US20220315603A1 (en) | 2022-10-06 |
| ZA202207543B (en) | 2023-12-20 |
| MX2022007993A (es) | 2022-07-21 |
| CN113365994A (zh) | 2021-09-07 |
| TW202413376A (zh) | 2024-04-01 |
| AU2020413997A1 (en) | 2022-06-09 |
| IL294136A (en) | 2022-08-01 |
| JP6948659B1 (ja) | 2021-10-13 |
| EP4083038A4 (en) | 2023-12-20 |
| CN115626919A (zh) | 2023-01-20 |
| CN115590854A (zh) | 2023-01-13 |
| CN115590854B (zh) | 2024-06-07 |
| WO2021132422A1 (ja) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22057324A (es) | Compuesto de piridazinil-tiazolcarboxamida | |
| DOP2023000107A (es) | Compuesto de heteroarilcarboxamida | |
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
| CO2019009680A2 (es) | Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo | |
| CO2017000754A2 (es) | Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo | |
| CO2018003500A2 (es) | Anticuerpos anti-pd-1 y composiciones | |
| CO2019007823A2 (es) | Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo | |
| CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
| CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
| CL2019001745A1 (es) | Conjugados anticuerpo droga para ablacion de celulas madre hematopoyeticas. | |
| BR112015028244A2 (pt) | Imunoconjugado que se liga ao folr1 e seu uso | |
| CL2016002835A1 (es) | “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| MX2020004334A (es) | Receptor de celulas t novedoso. | |
| AR104250A1 (es) | Anticuerpo anti-notch4 humano | |
| CO2018000652A2 (es) | Anticuerpo anti-epha4 | |
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| NZ729395A (en) | Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody | |
| NI202000031A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| BR112023001471A2 (pt) | Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| ECSP22021881A (es) | Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
| BR112022022713A2 (pt) | Dosagem e administração de anticorpo anti-ctla-4 ativável |